Compass Pathways' COMP360 achieved highly significant results in both Phase 3 trials for treatment-resistant depression — a condition that affects 100 million people worldwide and resists every conventional medication.
For the estimated 100 million people worldwide living with treatment-resistant depression — a form of the illness that does not respond to at least two conventional antidepressant medications — a breakthrough may finally be within reach. Compass Pathways announced that its synthetic psilocybin therapy COMP360 has now successfully achieved the primary endpoint in both of its Phase 3 clinical trials, clearing the most critical hurdle on the path to FDA approval. In the first trial, known as COMP005, a single 25-milligram dose of COMP360 versus placebo produced a highly statistically significant reduction in depression severity, with a p-value of less than 0.001 and a clinically meaningful difference of 3.6 points. The second trial, COMP006, tested two fixed doses of 25 milligrams versus a 1-milligram control and achieved an even stronger result — a 3.8-point reduction with the same level of statistical significance.
What makes these results remarkable is not just the numbers but the nature of the patient population. Treatment-resistant depression is, by definition, the hardest form of the disease to treat. These are patients who have already tried and failed on multiple medications, often over years or decades. Conventional antidepressants work by modulating serotonin, norepinephrine, or dopamine levels over weeks of daily dosing, and for roughly one in three depression patients, they simply do not work well enough. COMP360 operates through an entirely different mechanism — psilocybin binds to serotonin 5-HT2A receptors and triggers a cascade of neuroplastic changes that appear to reset dysfunctional brain circuits in a matter of hours rather than weeks. The therapy is administered in a single session under professional supervision, with most adverse effects — headache, nausea, and visual hallucination — occurring on the day of dosing and resolving within 24 hours in 88 percent of cases.
Compass Pathways plans to submit a New Drug Application to the FDA in the fourth quarter of 2026, which could make COMP360 one of the first psychedelic-derived medicines to receive full regulatory approval in the United States. The timing is significant. The FDA approved its second MDMA-assisted psychotherapy protocol for PTSD treatment in January 2026, with remission rates of 67 percent in Phase 3 trials — more than double the 20 to 30 percent achieved by current standard-of-care treatments. Together, these developments signal a fundamental shift in how psychiatry approaches treatment-resistant conditions. For decades, mental health treatment has relied on daily medication regimens that manage symptoms without addressing underlying brain circuit dysfunction. The emerging psychedelic therapy model — a single supervised dose that produces lasting neuroplastic change — represents what researchers are calling the most significant paradigm shift in psychiatric treatment since the introduction of SSRIs in the late 1980s. The question is no longer whether these therapies work. The question is how quickly healthcare systems can scale them to reach the millions of patients who need them.